A University of Kentucky study just published in Obstetrics & Gynecology shows that annual ultrasound screening of at-risk asymptomatic women increases the survival rates of women with type I and type II epithelial ovarian ...
Nov 1, 2018
0
1
A new 225Ac-DOTA-based pre-targeted radioimmunotherapy (PRIT) system has been shown to cure a highly lethal form of advanced intraperitoneal ovarian cancer in a preclinical setting with minimal side effects. Targeting the ...
Sep 18, 2023
0
23
Women who have ovarian cancer often develop a condition called ascites, which is a buildup of fluids in the abdomen. The most common treatment for ascites is puncturing the abdomen and manually draining the fluid, which is ...
Nov 17, 2015
0
65
A new streamlined approach to genetic testing for women with ovarian cancer provides testing rapidly and affordably, allowing many more patients to benefit from personalised cancer management and their relatives to benefit ...
Jul 13, 2016
0
44
Combing data collected on thousands of California ovarian cancer patients, UC Davis researchers have determined that almost one-third survived at least 10 years after diagnosis.
Aug 6, 2015
0
55
A new editorial paper was published in Oncoscience, titled, "UPR-induced ovarian cancer cell fusion: a mechanism favoring drug resistance?"
May 26, 2023
0
3
Research from Rutgers Cancer Institute of New Jersey and and other U.S. health and academic institutions shows a diet high in calcium and low in lactose may reduce the risk of ovarian cancer in African-American women. The ...
Sep 16, 2016
0
2
A molecule that helps control gene expression may play a role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer.
May 20, 2015
0
49
A genetic trawl through the DNA of almost 100,000 people, including 17,000 patients with the most common type of ovarian cancer, has identified 12 new genetic variants that increase risk of developing the disease and confirmed ...
Mar 27, 2017
0
80
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Jan 8, 2016
0
13
